Interestingly, DPP-4 inhibitors improve neurological prognosis after stroke in rodents, independent of GLP-1, possibly by increasing the bioavailability of other bioactive DPP-4 substrates, such as stromal cell-derived factor-1α (167). Here, DPP4 is linked to Stroke.